Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease (the FAST-M Study)
The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, is feasible for patients with myeloma precursor disease or newly diagnosed multiple myeloma.
• 18 years of age or older.
• Any sex/gender.
• Able to provide consent.
• Able to speak, read, and understand English or Spanish.
• Diagnosis of Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), or Multiple Myeloma (MM) per standard criteria:
∙ Cohort 1 - Participants must have a confirmed diagnosis of MGUS and SMM.
‣ Cohort 2 - Participants must have a confirmed new diagnosis of MM and be initiating anti-myeloma therapy.
• Delivery of anti-myeloma therapies at one of the following institutions:
∙ Sylvester Comprehensive Cancer Center (SCCC) (including satellite/network sites).
‣ University of Miami Health System.
• Approval from treating oncologist, confirmed via email or in writing.
• Eastern Cooperative Oncology Group (ECOG) Performance Status grade of \<2
• a. PI approval needed if ECOG ≥ 2.
• Having not consistently (not equal to or more than 50% of the time) engaged in structured fasting (i.e., not regularly fasting for ≥12hr/night) for the past 3 months.
⁃ Not consuming a Mediterranean diet by not meeting 2 or more out of the following 3 Mediterranean eating pattern goals in the prior 3 months: ≥3 servings of vegetables per day, ≥ 3 servings of beans and legumes per week, or ≥ 1 serving of nuts per day.
⁃ Mediterranean diet will be screened with select components of a Mediterranean Diet Adherence Screener (MEDAS).
⁃ Internet access on a smart phone, tablet, or computer.
⁃ Willing to be randomized to a prolonged overnight fasting and guided Mediterranean dietary intervention or waitlist-control group.